Výsledky vyhľadávania - "Atorvastatin therapeutic use"
-
1
Autori: a ďalší
Zdroj: Talasaz, A H, Sadeghipour, P, Bakhshandeh, H, Sharif-Kashani, B, Rashidi, F, Beigmohammadi, M T, Moghadam, K G, Rezaian, S, Dabbagh, A, Sezavar, S H, Farrokhpour, M, Abedini, A, Aliannejad, R, Riahi, T, Yadollahzadeh, M, Lookzadeh, S, Rezaeifar, P, Matin, S, Tahamtan, O, Mohammadi, K, Zoghi, E, Rahmani, H, Hosseini, S H, Mousavian, S M, Abri, H, Sadeghipour, P, Baghizadeh, E, Rafiee, F, Jamalkhani, S, Amin, A, Mohebbi, B, Parhizgar, S E, Soleimanzadeh, M, Aghakouchakzadeh, M, Eslami, V, Payandemehr, P, Khalili, H, Talakoob, H, Tojari, T, Shafaghi, S, Tabrizi, S, Kakavand, H, Kashefizadeh, A, Najafi, A, Jimenez, D, Gupta, A, Madhavan, M V, Sethi, S S, Parikh, S A, Monreal, M, Hadavand, N, Hajighasemi, A, Ansarin, K, Maleki, M, Sadeghian, S, Barco, S, Siegerink, B, Spatz, E S, Piazza, G, Kirtane, A J, Tassell, B W V, Lip, G Y H, Klok, F A, Goldhaber, S Z, Stone, G W, Krumholz, H M & Bikdeli, B 2023, 'Atorvastatin versus Placebo in ICU Patients with COVID-19 : Ninety-day Results of the INSPIRATION-S Trial', Thrombosis and Haemostasis, vol. 123, no. 7, pp. 723-733. https://doi.org/10.1055/a-2059-4844
Predmety: Atorvastatin/therapeutic use, Adult, Male, statin, Thrombosis/drug therapy, COVID-19, functional limitations, Thrombosis, atorvastatin, Middle Aged, 3. Good health, Intensive Care Units, Treatment Outcome, Double-Blind Method, lipid, Atorvastatin, Humans, Female
Popis súboru: application/pdf
-
2
Autori:
Zdroj: Basic Clin Pharmacol Toxicol
Predmety: Atorvastatin/therapeutic use, pharmacoepidemiology, Physicians', Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, misclassification, Incidence, Pharmacoepidemiology, Klinisk medicin, Practice Patterns, Original Articles, incidence, run-in, statins, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Atorvastatin, Humans, Clinical Medicine, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Practice Patterns, Physicians'
Popis súboru: application/pdf
-
3
Autori: a ďalší
Zdroj: Hepatol Commun
Kronborg, T M, Schierwagen, R, Trošt, K, Gao, Q, Moritz, T, Bendtsen, F, Gantzel, R H, Andersen, M L, Teisner, A S, Grønbæk, H, Hobolth, L, Møller, S, Trebicka, J & Kimer, N 2023, ' Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial ', Hepatology Communications, vol. 7, no. 12, e0332 . https://doi.org/10.1097/HC9.0000000000000332
Kronborg, T M, Schierwagen, R, Trošt, K, Gao, Q, Moritz, T, Bendtsen, F, Gantzel, R H, Andersen, M L, Teisner, A S, Grønbæk, H, Hobolth, L, Møller, S, Trebicka, J & Kimer, N 2023, 'Atorvastatin for patients with cirrhosis : A randomized, placebo-controlled trial', Hepatology Communications, vol. 7, no. 12, e0332. https://doi.org/10.1097/HC9.0000000000000332
Hepatology CommunicationsPredmety: Atorvastatin/therapeutic use, Liver Cirrhosis, Anti-Inflammatory Agents, Severity of Illness Index, 3. Good health, End Stage Liver Disease, Liver Cirrhosis/complications, Double-Blind Method, Hypertension, Portal/etiology, Hypertension, Hypertension, Portal, Atorvastatin, Portal/etiology, Humans, Original Article
Popis súboru: application/pdf
Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38051553
https://curis.ku.dk/ws/files/379594478/atorvastatin_for_patients_with_cirrhosis_a.10.pdf
https://pure.au.dk/portal/en/publications/6bdbc55b-30f6-4e5a-abec-cb681e12f8b8
https://doi.org/10.1097/HC9.0000000000000332
http://www.scopus.com/inward/record.url?scp=85186752478&partnerID=8YFLogxK -
4
Autori: a ďalší
Zdroj: Drugs Aging
Predmety: Male, Simvastatin, Tertiary Healthcare, Medizin, Age Factors, Myocardial Infarction, Coronary Artery Disease/blood [MeSH], Age Factors [MeSH], Aged [MeSH], Tertiary Care Centers [MeSH], Atorvastatin/therapeutic use [MeSH], Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration, Male [MeSH], Atorvastatin/administration, Original Research Article, Internal Medicine, Pharmacotherapy, Female [MeSH], Pharmacology/Toxicology, Geriatrics/Gerontology, Humans [MeSH], Coronary Artery Disease/drug therapy [MeSH], Simvastatin/administration, Retrospective Studies [MeSH], Middle Aged [MeSH], Cross-Sectional Studies [MeSH], Myocardial Infarction/drug therapy [MeSH], Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use [MeSH], Simvastatin/therapeutic use [MeSH], Tertiary Healthcare [MeSH], Germany [MeSH], Myocardial Infarction/blood [MeSH], Cholesterol, LDL/blood [MeSH], Cholesterol, LDL, Coronary Artery Disease, Middle Aged, 3. Good health, Tertiary Care Centers, 03 medical and health sciences, Cross-Sectional Studies, 0302 clinical medicine, Germany, Atorvastatin, Humans, Female, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Aged, Retrospective Studies
Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s40266-020-00768-9.pdf
https://pubmed.ncbi.nlm.nih.gov/32468428
https://link.springer.com/article/10.1007/s40266-020-00768-9
https://pubmed.ncbi.nlm.nih.gov/32468428/
https://europepmc.org/article/MED/32468428
https://link.springer.com/content/pdf/10.1007/s40266-020-00768-9.pdf
https://www.ncbi.nlm.nih.gov/pubmed/32468428
https://repository.publisso.de/resource/frl:6465107 -
5
Autori: a ďalší
Prispievatelia: a ďalší
Zdroj: Acta Médica Portuguesa, Vol 33, Iss 3 (2020)
Predmety: Diabetes Mellitus / diagnosis, Dislipidemias, Medicine (General), Dyslipidemias / drug therapy, Cholestasis / complications, Autoimmune Diseases / drug therapy, Hypothyroidism / drug therapy, Cirrose Hepática Biliar, Autoimmune Diseases, 03 medical and health sciences, R5-920, 0302 clinical medicine, Hypothyroidism, Atorvastatin / therapeutic use, Hypothyroidism / diagnosis, Atorvastatin, Diabetes Mellitus, Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use, Humans, Obesity, Hypothyroidism / complications, Dyslipidemias, Colestase, Cholestasis, Liver Cirrhosis, Biliary, Hipotiroidismo, Middle Aged, Obesity / complications, Thyroxine / therapeutic use, 3. Good health, Thyroxine, Withholding Treatment, Medicine, Female, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Liver Cirrhosis, Biliary / complications, Autoimmune Diseases / diagnosis, Dyslipidemias / etiology
Popis súboru: application/pdf
Prístupová URL adresa: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/download/9944/5891
https://pubmed.ncbi.nlm.nih.gov/32130100
https://doaj.org/article/230960152d0548798e2a4ba61c1ab83c
https://pubmed.ncbi.nlm.nih.gov/32130100/
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/download/9944/5891
https://www.ncbi.nlm.nih.gov/pubmed/32130100
https://europepmc.org/article/MED/32130100
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944
https://hdl.handle.net/10216/142530 -
6
Prispievatelia: a ďalší
Predmety: Aged, Atorvastatin* / administration & dosage, Atorvastatin* / adverse effects, Atorvastatin* / therapeutic use, Cholesterol, LDL* / blood, Coronary Artery Disease* / blood, Coronary Artery Disease* / complications, Coronary Artery Disease* / drug therapy, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors* / administration & dosage, Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use, Hyperlipoproteinemias* / blood, Hyperlipoproteinemias* / complications, Hyperlipoproteinemias* / drug therapy, Male, Middle Aged, Myocardial Infarction / etiology, Rosuvastatin Calcium* / administration & dosage, Rosuvastatin Calcium* / adverse effects, Rosuvastatin Calcium* / therapeutic use, Stroke / etiology, Treatment Outcome
Relation: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION; J01196; https://ir.ymlib.yonsei.ac.kr/handle/22282913/194174; https://jamanetwork.com/journals/jama/fullarticle/2802214; T202302527
-
7
Autori: a ďalší
Zdroj: Krasniqi, L, Brandes, A, Mortensen, P E, Dahl, J S, Gerke, O, Ali, M & Riber, L P S 2023, 'Atorvastatin and the influence on postoperative atrial fibrillation after surgical aortic valve replacement (STARC) in adults at Odense University Hospital, Denmark : study protocol for a randomised controlled trial', BMJ Open, vol. 13, no. 5, e069595. https://doi.org/10.1136/bmjopen-2022-069595
Predmety: Humans, Adult, Atorvastatin/therapeutic use, Atrial Fibrillation/etiology, Aortic Valve/surgery, Prospective Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Denmark, Hospitals, Postoperative Complications/etiology, Randomized Controlled Trials as Topic
Popis súboru: application/pdf
-
8
Autori: a ďalší
Predmety: Acute Coronary Syndrome/blood, Acute Coronary Syndrome/complications, Acute Coronary Syndrome/therapy, Aged, Antibodies, Monoclonal, Humanized/therapeutic use, Anticholesteremic Agents/therapeutic use, Atorvastatin/therapeutic use, Cholesterol, LDL/blood, Double-Blind Method, Feasibility Studies, Female, Hospitalization, Humans, Male, Middle Aged, Prospective Studies, LDL-C, PCSK9 inhibitor, acute coronary syndrome, evolocumab
Relation: Journal of the American College of Cardiology; https://iris.unil.ch/handle/iris/198177; serval:BIB_CE4FDCB10E8A; 000496502200003
-
9
Autori: a ďalší
Prispievatelia: a ďalší
Predmety: Aged, 80 and over, Aging, Amlodipine/adverse effects, Amlodipine/therapeutic use, Anti-Retroviral Agents/therapeutic use, Antiretroviral Therapy, Highly Active, Atorvastatin/adverse effects, Atorvastatin/therapeutic use, Cardiovascular Agents/adverse effects, Cardiovascular Agents/therapeutic use, Cardiovascular Diseases/drug therapy, Cardiovascular Diseases/epidemiology, Darunavir/adverse effects, Darunavir/therapeutic use, Drug Interactions, Female, HIV Infections/drug therapy, HIV Infections/epidemiology, Heterocyclic Compounds, 3-Ring/adverse effects, 3-Ring/therapeutic use, Humans, Male, Middle Aged, Oxazines/adverse effects, Oxazines/therapeutic use, Piperazines/adverse effects, Piperazines/therapeutic use
Relation: AIDS; https://iris.unil.ch/handle/iris/148605; serval:BIB_6666EE49EABD; 000562484200019
-
10
Autori: a ďalší
Zdroj: Int J Mol Sci
Predmety: Atorvastatin/therapeutic use, Male, Simvastatin, UK Biobank, exome sequencing variants, Liver-Specific Organic Anion Transporter 1/genetics, Exome Sequencing/methods, clinical response, Polymorphism, Single Nucleotide, Article, statinpresented here, Exome Sequencing, Atorvastatin, Humans, Polymorphism, Aged, pharmacogenomics, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use/adverse effects, Liver-Specific Organic Anion Transporter 1, statin, cholesterol, Single Nucleotide, Middle Aged, SLCO1B1, United Kingdom, Biological Specimen Banks, 3. Good health, Treatment Outcome, Simvastatin/therapeutic use, epidemiology, Female, Slco1b1, Hydroxymethylglutaryl-CoA Reductase Inhibitors
Popis súboru: 4426-; Electronic
Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38674010
-
11
Autori: a ďalší
Prispievatelia: a ďalší
Predmety: clinical, hyperlipidemias, medication adherence, pharmacology, stroke, Ischemic Stroke/drug therapy, Prospective Studies, Humans, Cholesterol, LDL, Male, Multicenter Studies as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Female, Aged, Atorvastatin/therapeutic use, Cardiology and Cardiovascular Medicine, Research Support, Non-U.S. Gov't, Journal Article
Popis súboru: application/pdf
Dostupnosť: https://dspace.library.uu.nl/handle/1874/447253
-
12
Autori: a ďalší
Prispievatelia: a ďalší
Zdroj: Open Heart
Open Heart, Vol 9, Iss 1 (2022)Predmety: Atorvastatin/therapeutic use, Male, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, hyperlipidemias, clinical, 03 medical and health sciences, 0302 clinical medicine, Journal Article, Atorvastatin, Diseases of the circulatory (Cardiovascular) system, Humans, Multicenter Studies as Topic, Prospective Studies, Aged, Ischemic Stroke, Research Support, Non-U.S. Gov't, Cholesterol, LDL, stroke, Cardiac Risk Factors and Prevention, 3. Good health, RC666-701, medication adherence, Female, Ischemic Stroke/drug therapy, pharmacology, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiology and Cardiovascular Medicine
Popis súboru: application/pdf
-
13
Autori: a ďalší
Zdroj: BMC Psychiatry
BMC Psychiatry, Vol 18, Iss 1, Pp 1-7 (2018)
Fotso Soh, J, Torres-Platas, S G, Beaulieu, S, Mantere, O, Platt, R, Mucsi, I, Saury, S, Renaud, S, Levinson, A, Andreazza, A C, Mulsant, B H, Müller, D, Schaffer, A, Dols, A, Cervantes, P, Low, N C, Herrmann, N, Christensen, B M, Trepiccione, F, Rajji, T & Rej, S 2018, 'Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus : the protocol of a randomized controlled trial', BMC Psychiatry, vol. 18, no. 1, 227. https://doi.org/10.1186/s12888-018-1793-9, https://doi.org/10.1186/s12888-018-1793-9
Fotso Soh, J, Torres-Platas, S G, Beaulieu, S, Mantere, O, Platt, R, Mucsi, I, Saury, S, Renaud, S, Levinson, A, Andreazza, A C, Mulsant, B H, Müller, D, Schaffer, A, Dols, A, Cervantes, P, Low, N C, Herrmann, N, Christensen, B M, Trepiccione, F, Rajji, T & Rej, S 2018, 'Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus : the protocol of a randomized controlled trial', BMC Psychiatry, vol. 18, no. 1, 227. https://doi.org/10.1186/s12888-018-1793-9Predmety: Atorvastatin/therapeutic use, Adult, Male, Canada, Bipolar Disorder, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Adolescent, Nephrogenic diabetes insipidus, Canada/epidemiology, RC435-571, Diabetes Insipidus, Nephrogenic, Kidney/drug effects, Lithium, Kidney, Study Protocol, Young Adult, 03 medical and health sciences, Kidney function, 0302 clinical medicine, Double-Blind Method, 80 and over, Atorvastatin, Humans, Lithium Compounds/adverse effects, Urinary osmolality, Placebo, Randomized clinical trial, Aged, Psychiatry, Aged, 80 and over, Depressive Disorder, Depressive Disorder, Major, Middle Aged, Bipolar Disorder/drug therapy, Nephrogenic/chemically induced, 3. Good health, Cross-Sectional Studies, Major/drug therapy, Lithium Compounds, Female, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Insipidus
Popis súboru: application/pdf
Prístupová URL adresa: https://bmcpsychiatry.biomedcentral.com/track/pdf/10.1186/s12888-018-1793-9
https://europepmc.org/articles/pmc6048831?pdf=render
https://pubmed.ncbi.nlm.nih.gov/30012135
https://doaj.org/article/b1bbd3ac2f414c68ab2ac7372bc7c78e
https://www.sciencedirect.com/science/article/abs/pii/S1064748119300788
https://tspace.library.utoronto.ca/handle/1807/90912
https://doaj.org/article/b1bbd3ac2f414c68ab2ac7372bc7c78e
https://www.narcis.nl/publication/RecordID/oai%3Apure.atira.dk%3Apublications%2F455cde75-ab81-42db-82d1-9678f136c364
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048831/
https://research.vumc.nl/en/publications/atorvastatin -in-the-treatment-of-lithium-induced-nephrogenic-diab
https://europepmc.org/article/MED/30012135
https://link.springer.com/content/pdf/10.1186/s12888-018-1793-9.pdf
https://research.vumc.nl/en/publications/455cde75-ab81-42db-82d1-9678f136c364
https://pure.amsterdamumc.nl/en/publications/6b89f6cd-c6bb-47ca-b29a-77835cd48eb9
https://doi.org/10.1186/s12888-018-1793-9
https://hdl.handle.net/11591/400211
https://doi.org/10.1186/s12888-018-1793-9 -
14
Autori: Gebbers, JO
Zdroj: GMS German Medical Science; VOL: 5; DOC04 /20070816/
Predmety: CORONARY ARTERIOSCLEROSIS/diet therapy, CORONARY ARTERIOSCLEROSIS/drug therapy, CORONARY ARTERIOSCLEROSIS/prevention & control, ATHEROSCLEROSIS, ATHEROSCLEROSIS/*diet therapy, ATHEROSCLEROSIS/*drug therapy, ATHEROSCLEROSIS/*prevention & control, ATHEROSCLEROSIS/*etiology, ATHEROSCLEROSIS/immunology, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS/*therapeutic use, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS/*pharmacology, ATORVASTATIN/therapeutic use, ATORVASTATIN/pharmacology, SIMVASTATIN/therapeutic use, SIMVASTATIN/pharmacology, CHOLESTEROL/blood, CHOLESTEROL/pharmacology, CHOLESTEROL/pathology, DIET, MEDITERRANEAN, FAT-RESTRICTED, FOLIC ACID/metabolism, FOLIC ACID/pharmacology, HOMOCYSTEINE/metabolism, HOMOCYSTEINE/pharmacology, HOMOCYSTEINE/blood, MICRONUTRIENTS/pharmacology, VITAMIN B COMPLEX/metabolism, RISK FACTORS
Relation: Heart disease and stroke statistics - 2004 update. Dallas: American Heart Association, 2003.; Avorn J. Torcetrapib and atorvastatin--should marketing drive the research agenda? N Engl J Med. 2005;352(25):2573-6.; Arbor Clinical Nutrition Update. Homocysteine and heart disease in 2006. 2006;258. Available from: http://www.nutritionupdates.org/sub/sub03.php?item=2; Get ready for statin price wars. Marketplace 2006 June 23. Available from: http://marketplace.publicradio.org/shows/2006/06/23/PM200606234.html.; Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274(13):1049-57.; Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 2005;1(5):309-22.; Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Oxford: Clinical Trial Service Unit; 2006 [updated 2006 May 16; cited 2007 Aug 08]. Available from: http://www.ctsu.ox.ac.uk/projects/search/index_html; Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-16.; Cornhill JF, Roach MR. A quantitative study of the localization of atherosclerotic lesions in the rabbit aorta. Atherosclerosis. 1976;23(3):489-501.; de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779-85.; del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, Alegret M, Pena JM, Rodriguez-Zapata M, Alvarez-Mon M, Martinez-A C, Manes S. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med. 2004;200(4):541-7.; Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004;292(12):1440-6.; Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ruiz-Gutierrez V, Covas MI, Fiol M, Gomez-Gracia E, Lopez-Sabater MC, Vinyoles E, Aros F, Conde M, Lahoz C, Lapetra J, Saez G, Ros E; PREDIMED Study Investigators. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med. 2006;145(1):1-11.; Faggiotto A, Paoletti R. State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension. 1999;34(4 Pt 2):987-96.; Finsterer J. Fibrat und Statin-Myopathie [Fibrate and statine myopathy]. Nervenarzt. 2003;74(2):115-22.; Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci U S A. 2004;101(17):6659-63.; Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology. 2002;58(9):1333-7.; Gebbers JO. Cholesterin ist für die Atherosklerose ohne Bedeutung. Die Ergebnisse von Autopsien stützen die Lipidhypothese nicht. Ars Medici. 1998;88:564-9.; Giannini O, Gebbers JO. Fragwürdige KHK-Epidemiologie. Ars Medici. 1999;89(5):320-5.; Gimbrone MA, Topper JN. Biology of the Vessel Wall: Endothelium. In: Chien KR, editor. Molecular Basis of Heart Diseases. Troy, MO: Hartcourt Brace; 1998. p. 331-48; Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-90.; Grimes DS. Are statins analogues of vitamin D? Lancet. 2006;368(9529):83-6.; Hall IH, Chen SY, Rajendran KG, Sood A, Spielvogel BF, Shih J. Hypolipidemic, anti-obesity, anti-inflammatory, anti-osteoporotic, and anti-neoplastic properties of amine carboxyboranes. Environ Health Perspect. 1994;102 Suppl 7:21-30.; Hansson GK. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol. 1997;8(5):301-11.; Hansson GK, Zhou X, Tornquist E, Paulsson G. The role of adaptive immunity in atherosclerosis. Ann N Y Acad Sci. 2000;902:53-64.; Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006;145(7):520-30.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.; Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem. 2001;276(1):40-7.; Kleist P. Zehn Anforderungen an therapeutische Äquivalenzstudien. Oder warum der fehlende Nachweis von Unterschieden und Äquivalenz nicht dasselbe bedeuten. Swiss Med Forum. 2006;6(37):814-9.; Knoops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A, van Staveren WA. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004;292(12):1433-9.; Krapf R. BMI oder: Wer ist überhaupt noch normalgewichtig? Swiss Med Forum. 2004;4(50):1265.; Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6(12):1399-402.; Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97(12):1129-35.; Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106(4):523-31.; Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118.; Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG, van Veldhuisen DJ; Folic Acid on Risk Diminishment After Acute Myocarial Infarction Study Group. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. Int J Cardiol. 2004;93(2-3):175-9.; Matsuno H, Takei M, Hayashi H, Nakajima K, Ishisaki A, Kozawa O. Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries. J Cardiovasc Pharmacol. 2004;43(3):333-40.; McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111-28.; McNulty H, Dowey le RC, Strain JJ, Dunne A, Ward M, Molloy AM, McAnena LB, Hughes JP, Hannon-Fletcher M, Scott JM. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C->T polymorphism. Circulation. 2006;113(1):74-80.; Moat SJ, Doshi SN, Lang D, McDowell IF, Lewis MJ, Goodfellow J. Treatment of coronary heart disease with folic acid: is there a future? Am J Physiol Heart Circ Physiol. 2004;287(1):H1-7.; Moat SJ, Lang D, McDowell IF, Clarke ZL, Madhavan AK, Lewis MJ, Goodfellow J. Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem. 2004;15(2):64-79.; Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. N Engl J Med. 2006;354(15):1601-13.; Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29-38.; Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med. 2000;247(3):371-80.; Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, Tverdal A, Tell GS, Nygard O, Vollset SE. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr. 2006;136(6 Suppl):1731S-1740S.; Resnick N, Gimbrone MA Jr. Hemodynamic forces are complex regulators of endothelial gene expression. FASEB J. 1995;9(10):874-82.; Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20-8.; Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990;75(4):895-901.; Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340(2):115-26.; Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-9.; Scrimshaw NS, Guzman MA. Diet and atherosclerosis. Lab Invest. 1968;18(5):623-8.; Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-7.; Silverberg C. Atorvastatin-induced polyneuropathy. Ann Intern Med. 2003;139(9):792-3.; Spieker L, Ruschitzka F, Lüscher TF, Noll G. HDL-Cholesterin bei Atherosklerose - zu wenig des Guten. Swiss Med Forum. 2003;3(39):920-6.; Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Lüscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105(12):1399-402.; Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91(1):308-18.; Stehbens WE, Smith RL. Serum cholesterol correlations with atherosclerosis at autopsy. Am Clin Lab. 1997;16(3):14-5.; Strong JP, Johnson WD, Oalmann MC, Wissler RW. Community pathology of atherosclerosis and coronary heart disease in New Orleans: Relationship of risk factors to atherosclerotic lesions. In: Gotto AM, Smith LC, Allen B, editors. Atherosclerosis V. New York, NY: Springer; 1980. p. 719-30.; Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP 3rd, Herderick EE, Cornhill JF. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999;281(8):727-35.; Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002;87(2):563-8.; Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1998;31(3):552-7.; Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: RB Francis, editor. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker; 1992. p. 183-236.; Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. BMJ. 2005;331(7517):614.; Virchow R. Der atheromatöse Prozess der Arterien. Wien Med Wochenschr. 1856;6:825-41.; van de Ree MA, Huisman MV, de Man FH, van der Vijver JC, Meinders AE, Blauw GJ. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res. 2001;52(2):299-305.; van Etten RW, de Koning EJ, Verhaar MC, Gaillard CA, Rabelink TJ. Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia. 2002;45(7):1004-10.; van Etten RW, de Koning EJ, Honing ML, Stroes ES, Gaillard CA, Rabelink TJ. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol. 2002;22(5):799-804.; Wolfe SM. Dangers of rosuvastatin identified before and after FDA approval. Lancet. 2004;363(9427):2189-90.; http://www.egms.de/en/journals/gms/2007-5/000040.shtml
-
15
Autori: Gebbers, JO
Zdroj: GMS German Medical Science, Vol 5, p Doc04 (2007)
GMS German Medical Science; VOL: 5; DOC04 /20070816/Predmety: Ernährung, Simvastatin, FOLSÄURE/Pharmakologie, B-Vitamine, CHOLESTEROL/pharmacology, ATHEROSCLEROSIS/*prevention & control, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS/*pharmacology, HYDROXYMETHYLGLUTARYL-COA-REDUCTASE-INHIBITOREN/*therapeutische Anwendung, Mediterrane Ernährung, ATHEROSKLEROSE/*Diättherapie, ATHEROSKLEROSE/*Verhütung & Bekämpfung, 0302 clinical medicine, ATORVASTATIN/pharmacology, Atorvastatin, KORONARSKLEROSE/Verhütung & Bekämpfung, ATHEROSCLEROSIS/*drug therapy, ATHEROSCLEROSIS/*etiology, DIET, FAT-RESTRICTED, CHOLESTEROL/Pathologie, CHOLESTEROL/pathology, HOMOCYSTEIN/Stoffwechsel, SIMVASTATIN/therapeutic use, HOMOCYSTEIN/Pharmakologie, SIMVASTATIN/pharmacology, ESSENTIELLE SPURENELEMENTE/Pharmakologie, HYDROXYMETHYLGLUTARYL-COA-REDUCTASE-INHIBITOREN, 3. Good health, nutrition, ATHEROSKLEROSE/Immunologie, ddc: 610, SIMVASTATIN/Pharmakologie, CHOLESTEROL/blood, RISK FACTORS, DIÄT, FETTREDUZIERTE, Medicine, lipid-hypothesis, Mikro-Nahrungsbestandteile, HOMOCYSTEINE/metabolism, KORONARSKLEROSE/Arzneimitteltherapie, ATHEROSKLEROSE/*Arzneimitteltherapie, Homozystein, Mediterranean-style nutrition, REVIEW LITERATURE, ATHEROSKLEROSE/*Ätiologie, DIÄT, MITTELMEER, ÜBERSICHTSLITERATUR, HYDROXYMETHYLGLUTARYL-COA-REDUCTASE-INHIBITOREN/*Pharmakologie, FOLIC ACID/metabolism, CORONARY ARTERIOSCLEROSIS/prevention & control, MICRONUTRIENTS/pharmacology, ATHEROSCLEROSIS, HOMOCYSTEINE/blood, ATHEROSKLEROSE, folate, SIMVASTATIN/therapeutische Anwendung, Atherosklerose, statins, ATORVASTATIN/therapeutic use, DIET, MEDITERRANEAN, CORONARY ARTERIOSCLEROSIS/drug therapy, 03 medical and health sciences, VITAMIN-B-KOMPLEX/Stoffwechsel, B-vitamins, KORONARSKLEROSE/Diättherapie, VITAMIN B COMPLEX/metabolism, FOLIC ACID/pharmacology, RISIKOFAKTOREN, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS, FOLSÄURE/Stoffwechsel, Folsäure, ATHEROSCLEROSIS/immunology, CHOLESTEROL/Blut, cholesterol, homocysteine, ATHEROSCLEROSIS/*diet therapy, HOMOCYSTEINE/pharmacology, CHOLESTEROL/Pharmakologie, HOMOCYSTEIN/Blut, Statine, Lipid-Hypothese, micronutrients, Pharmakologie, Cholesterin, therapeutische Anwendung, atherosclerosis, CORONARY ARTERIOSCLEROSIS/diet therapy, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS/*therapeutic use
-
16
Autori: a ďalší
Predmety: systemic sclerosis, atorvastatin, modified Rodnan score, Scleroderma, Systemic--physiopathology, Systemic--drug therapy, Atorvastatin--therapeutic use
Popis súboru: application/pdf
-
17
Autori:
Zdroj: Texas Heart Institute journal [Tex Heart Inst J] 2015 Dec 01; Vol. 42 (6), pp. 528-36. Date of Electronic Publication: 2015 Dec 01 (Print Publication: 2015).
Spôsob vydávania: Journal Article; Randomized Controlled Trial
Informácie o časopise: Publisher: published in the Cardiovascular Surgical Research Laboratories, Texas Heart Institute Country of Publication: United States NLM ID: 8214622 Publication Model: eCollection Cited Medium: Internet ISSN: 1526-6702 (Electronic) Linking ISSN: 07302347 NLM ISO Abbreviation: Tex Heart Inst J Subsets: MEDLINE
Výrazy zo slovníka MeSH: Percutaneous Coronary Intervention*/adverse effects, Acute Coronary Syndrome/*therapy , Atorvastatin/*administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage, Acute Coronary Syndrome/blood ; Acute Coronary Syndrome/diagnosis ; Acute Coronary Syndrome/physiopathology ; Aged ; Atorvastatin/adverse effects ; Biomarkers/blood ; C-Reactive Protein/metabolism ; Down-Regulation ; Drug Administration Schedule ; Egypt ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Male ; Middle Aged ; Prospective Studies ; Stroke Volume/drug effects ; Systole ; Time Factors ; Treatment Outcome ; Ventricular Function, Left/drug effects
Nájsť tento článok vo Web of Science 
Full Text Finder 
Full Text